Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy W Jones

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
International Psychogeriatrics|August 27, 2015
Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's diseaseCatherine Reed, Mark Belger, Bruno Vellas, et al.
Alzheimer'S Research & Therapy|September 21, 2016
Drug development in Alzheimer's disease: the path to 2025Jeffrey Cummings, Paul S Aisen, Bruno DuBois, et al.
Aging & Mental Health|March 7, 2019
Psychological predictors of 'living well' with dementia: findings from the IDEAL studyRuth A Lamont, Sharon M Nelis, Catherine Quinn, et al.
Dementia and Geriatric Cognitive Disorders Extra|June 15, 2017
Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver OutcomesRoy W Jones, Jeremie Lebrec, Kristin Kahle-Wrobleski, et al.
Journal of Alzheimer'S Disease : JAD|May 1, 2013
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findingsAnders Wimo, Catherine C Reed, Richard Dodel, et al.
BMC Medical Research Methodology|July 20, 2016
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational studyMark Belger, Josep Maria Haro, Catherine Reed, et al.
Lancet (London, England)|July 22, 2008
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trialClive Holmes, Delphine Boche, David Wilkinson, et al.
Aging & Mental Health|December 11, 2023
Dyadic perspectives on loneliness and social isolation among people with dementia and spousal carers: findings from the IDEAL programmeIsla Rippon, Christina R Victor, Anthony Martyr, et al.
Alzheimer'S Research & Therapy|August 11, 2017
On the path to 2025: understanding the Alzheimer's disease continuumPaul S Aisen, Jeffrey Cummings, Clifford R Jack, et al.
European Journal of Neurology|December 28, 2020
European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairmentKristian Steen Frederiksen, T Rune Nielsen, Bengt Winblad, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
International Psychogeriatrics|August 27, 2015
Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's diseaseCatherine Reed, Mark Belger, Bruno Vellas, et al.
Alzheimer'S Research & Therapy|September 21, 2016
Drug development in Alzheimer's disease: the path to 2025Jeffrey Cummings, Paul S Aisen, Bruno DuBois, et al.
Aging & Mental Health|March 7, 2019
Psychological predictors of 'living well' with dementia: findings from the IDEAL studyRuth A Lamont, Sharon M Nelis, Catherine Quinn, et al.
Dementia and Geriatric Cognitive Disorders Extra|June 15, 2017
Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver OutcomesRoy W Jones, Jeremie Lebrec, Kristin Kahle-Wrobleski, et al.
Journal of Alzheimer'S Disease : JAD|May 1, 2013
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findingsAnders Wimo, Catherine C Reed, Richard Dodel, et al.
BMC Medical Research Methodology|July 20, 2016
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational studyMark Belger, Josep Maria Haro, Catherine Reed, et al.
Lancet (London, England)|July 22, 2008
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trialClive Holmes, Delphine Boche, David Wilkinson, et al.
Aging & Mental Health|December 11, 2023
Dyadic perspectives on loneliness and social isolation among people with dementia and spousal carers: findings from the IDEAL programmeIsla Rippon, Christina R Victor, Anthony Martyr, et al.
Alzheimer'S Research & Therapy|August 11, 2017
On the path to 2025: understanding the Alzheimer's disease continuumPaul S Aisen, Jeffrey Cummings, Clifford R Jack, et al.
European Journal of Neurology|December 28, 2020
European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairmentKristian Steen Frederiksen, T Rune Nielsen, Bengt Winblad, et al.
Pageof 9